INT68829

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 1997
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 14
Total Number 16
Disease Relevance 7.96
Pain Relevance 2.00

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Golgi apparatus (ELF3) nucleolus (ELF3) nucleus (ELF3)
extracellular matrix organization (ELF3) embryo development (ELF3) cytoplasm (ELF3)
Anatomy Link Frequency
kidney 2
urine 2
ERg 1
platelet 1
ELF3 (Homo sapiens)
Pain Link Frequency Relevance Heat
fluoxetine 6 96.76 Very High Very High Very High
Pain 123 96.56 Very High Very High Very High
rheumatoid arthritis 9 93.20 High High
Bioavailability 1 87.96 High High
fibrosis 45 86.44 High High
depression 26 84.28 Quite High
Codeine 16 82.64 Quite High
Multiple sclerosis 6 76.24 Quite High
cva 31 76.04 Quite High
Central nervous system 37 74.76 Quite High
Disease Link Frequency Relevance Heat
Proteinuria 408 99.84 Very High Very High Very High
Fabry Disease 796 99.80 Very High Very High Very High
Disease 340 98.80 Very High Very High Very High
Pain 142 96.56 Very High Very High Very High
Targeted Disruption 8 95.24 Very High Very High Very High
Gauchers Disease 67 93.56 High High
Rheumatoid Arthritis 9 93.20 High High
Renal Disease 251 92.28 High High
Rheumatic Fever 6 90.96 High High
Systemic Lupus Erythematosus 9 89.60 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
There was a significant interaction between ERT status and treatment effect (P = 0.015).
ERT Binding (interaction) of
1) Confidence 0.47 Published 1997 Journal Am J Geriatr Psychiatry Section Abstract Doc Link 9106373 Disease Relevance 0.16 Pain Relevance 0.57
The future rate of decline of GFR In patients with Fabry disease can be predicted from the baseline proteinuria at the time of initiation of ERT if urine protein excretion is not controlled (Figure 9).
ERT Binding (initiation) of in urine associated with proteinuria and fabry disease
2) Confidence 0.34 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 1.07 Pain Relevance 0
After adjustment for baseline proteinuria, the intention-to-treat analysis showed that ERT was associated with a 53% risk reduction in the primary event rate, although due to the small number of patients in the trial the results did not reach statistically significance (p = 0.058).
ERT Binding (associated) of associated with proteinuria
3) Confidence 0.33 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 0.84 Pain Relevance 0.14
While there is ongoing debate about the optimal timing for initiating ERT, especially in pediatric patients, the recent biopsy studies argue against waiting until there is demonstrated kidney damage as evidenced by reduced eGFR or overt proteinuria before initiating ERT.
ERT Binding (initiating) of in kidney associated with proteinuria
4) Confidence 0.30 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 0.66 Pain Relevance 0.04
Transplant and dialysis patients, and patients in whom kidney function has been stabilized with ERT and control of proteinuria with ACEI/ARB therapy would be appropriate subjects for these prospective studies.Just as anti-proteinuric therapy appears to be important adjuncts for ERT in Fabry nephropathy, the usefulness of similar adjuncts to ERT for the cardiovascular and cerebrovascular manifestations of Fabry disease need to be explored.
ERT Binding (stabilized) of in kidney associated with renal disease, proteinuria and fabry disease
5) Confidence 0.30 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 0.96 Pain Relevance 0
It admits no doubt that ERT should be initiated in carriers with substantial disease manifestations as well as all affected male patients with Fabry disease as early as possible to prevent irreversible major organ damage (12, 26-28).
ERT Binding (initiated) of associated with fabry disease and disease
6) Confidence 0.27 Published 2008 Journal Journal of Korean Medical Science Section Body Doc Link PMC2526436 Disease Relevance 0.49 Pain Relevance 0.05
Because of their minimal variations during ERT, hemoglobin levels were not included in this model.
ERT Binding (variations) of
7) Confidence 0.23 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2945057 Disease Relevance 0.09 Pain Relevance 0
Splenectomized patients' platelet counts rose slightly under ERT, with no significant slope change, while nonsplenectomized patients' counts increased significantly from baseline under ERT but returned to normal after 6.5 years of treatment.
ERT Neg (no) Binding (rose) of in platelet
8) Confidence 0.20 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2945057 Disease Relevance 0.05 Pain Relevance 0
Based on these limitations, plus the high cost of ERT, the need for weekly infusions over a lifetime, and the possibility of immune-based reactions that may complicate therapy, the critical question is: should cellular therapy be used alone or integrated as multimodal therapy with ERT to best provide optimal correction of IDUA deficiency?


ERT Binding (therapy) of
9) Confidence 0.18 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727896 Disease Relevance 0 Pain Relevance 0.03
In light of this, we chose to investigate prospectively the combination of ERT and HCT, utilizing a single conditioning regimen, receiving a similar number of enzyme infusions, and providing consistent supportive care in a single transplant center (Tolar et al 2007).
ERT Binding (combination) of
10) Confidence 0.18 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727896 Disease Relevance 0.14 Pain Relevance 0
This article gives an overview of the clinical manifestations, diagnosis and symptomatic management of patients with MPS II and provides, for the first time, recommendations for the use of ERT.


ERT Binding (recommendations) of
11) Confidence 0.16 Published 2007 Journal Eur J Pediatr Section Body Doc Link PMC2234442 Disease Relevance 0.33 Pain Relevance 0.06
Before initiation of ERT, QoL was worse in patients with FD than in the general population.
ERT Binding (initiation) of associated with fabry disease
12) Confidence 0.15 Published 2010 Journal Orphanet J Rare Dis Section Body Doc Link PMC3009617 Disease Relevance 1.18 Pain Relevance 0.68
From urinary Gb3 studies, it appears that persistence of antibodies impairs ERT at a dose of 0.2 mg/kg EOW.
ERT Binding (impairs) of
13) Confidence 0.15 Published 2010 Journal Orphanet J Rare Dis Section Body Doc Link PMC3009617 Disease Relevance 0.22 Pain Relevance 0
In the interest of future research, biobanking of plasma, serum and urine samples remains highly recommended in all patients affected with FD prior to initiation of ERT.


ERT Binding (initiation) of in urine associated with fabry disease
14) Confidence 0.15 Published 2010 Journal Orphanet J Rare Dis Section Body Doc Link PMC3009617 Disease Relevance 1.28 Pain Relevance 0.18
The duration of thyroarytenoid EMG activity associated with ERt was shorter than that in ERg.
ERt Binding (associated) of in ERg
15) Confidence 0.14 Published 2008 Journal Cough Section Abstract Doc Link PMC2405785 Disease Relevance 0.14 Pain Relevance 0.16
This model has been used for experiments with ERT, SRT, and gene therapy.
ERT Binding (experiments) of
16) Confidence 0.12 Published 2010 Journal Current Chemical Genomics Section Body Doc Link PMC2995157 Disease Relevance 0.34 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox